Cocrystal Pharma, Inc. announced the appointment of Carol L. Brosgart, MD to its Board of Directors, effective August 12, 2026. Dr. Brosgart brings extensive experience in antiviral therapy and biopharma advisory, having contributed to FDA-approved therapies at Gilead Sciences and served on boards at Galmed Pharmaceuticals and Eradivir Biotech. Her appointment aims to provide clinical insights for advancing the development of CDI-988 for norovirus and the broader antiviral pipeline. Cocrystal Pharma is a clinical-stage biotechnology company developing novel antiviral therapeutics targeting noroviruses, influenza, coronaviruses, and hepatitis C.
